Abiomed Inc
ABMDDelisted Dec 22, 2022- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000815094
Abiomed Inc was delisted on Dec 22, 2022; its insiders filed their last Form 4 on Dec 27, 2022; 516 institutions reported holding it in 13F filings for Q3 2022, worth $10.6B in total; Maverick Capital was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 11:38 AM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 28, 2022 | Apr 29, 2021 | Apr 30, 2020 | May 2, 2019 | May 3, 2018 |
| Revenue | $1.03B | $847.5M | $840.9M | $769.4M | $593.7M |
| Cost of revenue | $188.2M | $161.9M | $151.3M | $129.6M | $98.6M |
| Operating expenses | – | $456.1M | $440.4M | $415.1M | $338.0M |
| Research and development | $163.4M | $121.9M | $98.8M | $93.5M | $75.3M |
| Selling, general and administrative | $423.5M | $334.2M | $341.6M | $321.6M | $262.7M |
| Operating income | $140.7M | $229.6M | $249.2M | $224.8M | $157.1M |
| Income tax | $54.1M | $62.7M | $53.8M | $4.34M | $48.3M |
| Net income | $136.5M | $225.5M | $203.0M | $259.0M | $112.2M |
| EPS, basic | $3.00 | $5.00 | $4.49 | $5.77 | $2.54 |
| EPS, diluted | $2.98 | $4.94 | $4.43 | $5.61 | $2.45 |
| Weighted shares, basic | 45.4K | 45.1M | 45.2M | 44.9M | 44.2M |
| Weighted shares, diluted | 45.9M | 45.7M | 45.8M | 46.2M | 45.8M |
| Margins and growth | |||||
| Operating margin | 13.6% | 27.1% | 29.6% | 29.2% | 26.5% |
| Net margin | 13.2% | 26.6% | 24.1% | 33.7% | 18.9% |
| Revenue growth, year over year | +21.7% | +0.8% | +9.3% | +29.6% | +33.3% |
| Net income growth, year over year | −39.5% | +11.1% | −21.6% | +130.9% | +115.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 28, 2022 | Apr 29, 2021 | Apr 30, 2020 | May 2, 2019 | May 3, 2018 |
| Cash and equivalents | $132.8M | $232.7M | $192.3M | $121.0M | $43.0M |
| Short-term investments | – | $351.0M | $250.8M | $370.7M | $319.3M |
| Accounts receivable | $90.6M | $97.2M | $84.7M | $90.8M | $70.0M |
| Inventory | – | $81.1M | $90.1M | $80.9M | $50.2M |
| Total current assets | $976.5M | $788.0M | $635.9M | $677.2M | $494.3M |
| Property, plant and equipment | $202.5M | $197.1M | $164.9M | $145.0M | $117.2M |
| Goodwill | $76.8M | $78.6M | $32.0M | $32.6M | $35.8M |
| Total assets | $1.67B | $1.49B | $1.22B | $1.05B | $786.4M |
| Accounts payable | $35.3M | $34.8M | $32.8M | $32.2M | $23.6M |
| Total current liabilities | $138.5M | $129.0M | $131.9M | $106.0M | $84.7M |
| Total liabilities | $170.1M | $164.7M | $151.0M | $117.5M | $96.9M |
| Shareholders' equity | $1.50B | $1.33B | $1.07B | $936.9M | $689.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 28, 2022 | Apr 29, 2021 | Apr 30, 2020 | May 2, 2019 | May 3, 2018 |
| Operating cash flow | $285.4M | $274.6M | $314.9M | $252.2M | – |
| Capital expenditures | $35.8M | $53.4M | $44.0M | $44.0M | $55.9M |
| Free cash flow | $249.6M | $221.2M | $270.9M | $208.2M | – |
| Depreciation and amortization | $28.1M | $24.1M | $20.4M | $14.1M | $11.0M |
| Stock-based compensation | $52.7M | $47.0M | $39.8M | $54.5M | $40.4M |
| Share buybacks | – | $11.3M | $84.9M | – | – |
| Investing cash flow | -$381.0M | -$223.3M | -$125.5M | -$116.5M | – |
| Financing cash flow | -$2.20M | -$8.07M | -$117.7M | -$55.8M | – |
| Net change in cash | -$99.9M | $40.4M | $71.3M | $78.0M | $3.94M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5.1% | 5.5% | 4.7% | 7.1% | 6.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.